Mylan will be launching two new HIV treatments, Symfi Lo (efavirenz, lamivudine, tenofovir disoproxil fumarate) and Cimduo (lamivudine, tenofovir disoproxil fumarate), both approved by the Food and Drug Administration last month. Symfi Lo will be available in the coming weeks whereas Cimduo is expected in the second quarter of 2018.
Symfi Lo combines efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), and lamivudine (3TC) and tenofovir disoproxil fumarate (TDF), both nucleo(t)side reverse transcriptase inhibitors. It was approved by the Food and Drug Administration (FDA) as a complete regimen for the treatment of HIV-1 infection in adult and pediatric patients weighing ≥35kg.
Cimduo combines lamivudine and tenofovir disoproxil fumarate, two nucleo(t)side reverse transcriptase inhibitors. It is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing ≥35kg.
Mylan President Rajiv Malik, stated, “In particular, we believe the option to take a lower dose of efavirenz in a single-tablet regimen with Symfi Lo will be a welcome addition for patients and providers.”
Symfi Lo will be available as 400mg/300mg/300mg strength tablets and Cimduo will be available as 300mg/300mg strength tablets.
For more information call (877) 446-3679 or visit Mylan.com.